FEED Trial

Name No. For Patients with Purpose
FEED Trial 20-27

Participants must be 18 years or older and have been diagnosed with pancreatic cancer and been referred for chemotherapy at SVUH before potentially having surgery. Additional criteria applies.

Participants will participate in a 12 week multi-modal nutritional care package while undergoing standard chemotherapy for pancreatic cancer at SVUH. The care package consists of diet, supplements, daily step target and dietitian and physiotherapist appointments. Participants will be followed up for 6 months.


Name No. For Patients with Purpose
NEEDS 20-36

Advanced squamous cell carcinoma (SCC) of the oesophagus

The goal of the NEEDS study is to compare outcomes after neoadjuvant chemoradiotherapy (chemotherapy before surgery) plus esophagectomy to outcomes after definitive chemoradiotherapy (treatment is chosen as the main type of treatment and other treatment options e.g surgery are only used afterwards if they are required) with surveillance and salvage esophagectomy as needed in patients with resectable locally advanced squamous cell carcinoma (SCC) of the esophagus, with the aim to provide generalizeable guidance for future clinical practice

DP-IMRT Pancreas

Name No. For Patients with Purpose
DP-IMRT Pancreas 17-12

resectable or borderline resectable (per the National Comprehensive Cancer Network (NCCN) criteria) pancreatic adenocarcinoma.

to determine the maximum tolerated dose (MTD) defined by the number of radiotherapy-related ≥ Grade 3 acute toxicities assessed up to 4 weeks post RT. Once the MTD is established, patients will continue to be recruited at that dose level up to a total of 49 patients.


Name No. For Patients with Purpose
Mountaineer-03 23-25

Patients with HER2 positive colorectal cancer that has spread through the body (metastatic) and/or cannot be removed with surgery (unresectable).

The main objective of the study is to find out if tucatinib with other cancer drugs works better than standard of care to treat participants with HER2 positive colorectal cancer. This study will also test what side effects happen when participants take this combination of drugs.


Name No. For Patients with Purpose
FORTITUDE-101 23-17

Suitable for adult patients with previously untreated Gastric or Gastroesophageal Junction Cancer with FGFR2b Overexpression

The main objective of this study is to compare efficacy of bemarituzumab combined with oxaliplatin, leucovorin, and 5-fluorouracil (5-FU) (mFOLFOX6) to placebo plus mFOLFOX6 as assessed by overall survival (OS) in participants with Fibroblast Growth Factor Receptor 2b (FGFR2b) over expression.

PaTcH Trial

Name No. For Patients with Purpose
PaTcH Trial 20-27

Metastatic refractory pancreatic cancer treated with trametinib and hydroxychloroquine

The goal of this study is to examine if Trametinib and Hydroxychloroquine will improve results for patients with advanced pancreatic cancer compared to standard chemotherapy.

HERIZON-GEA-01 (ZWI-ZW25-301) Zymeworks

Name No. For Patients with Purpose
HERIZON-GEA-01 (ZWI-ZW25-301) Zymeworks 21-35

The patients in this study will have advanced human epidermal growth factor 2 (HER2)-positive stomach and esophageal cancers that are no longer treatable with surgery (unresectable) or chemoradiation, and/or have grown or spread to other parts of the body (metastatic)

This study is being done to find out if zanidatamab, when given with chemotherapy plus or minus tislelizumab, is safe and works better than trastuzumab given with chemotherapy.

DESTINY DS8201-A-U306  

Name No. For Patients with Purpose
DESTINY DS8201-A-U306   21-07

HER-2 positive metastatic and/or unresectable gastric or gasto-esophageal junction (GEJ) cancer

This study will evaluate the efficacy and safety of trastuzumab deruxtecan (T-DXd), a HER-2 targeting antinbody drug, compared with ramucirumab and paclitaxel (Ram + PTX) in participants with HER2-positive gastric or gastro-esophageal junction (GEJ) cancer who have progressed on or after a trastuzumab-containing regimen and have not received any additional systemic therapy.

Astellas 8951-CL-5201

Name No. For Patients with Purpose
Astellas 8951-CL-5201 CTRIAL-IE 18-44

Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma

The purpose of this study is to confirm the recommended phase 2 dose (RP2D) of zolbetuximab in combination with Nab-P + GEM, determine overall survival and assess the safety and tolerability of the combination treatment.

This study will also evaluate tumor markers and pharmacokinetics (PK) of zolbetuximab, Nab-P and GEM, and health-related quality of life (HRQoL).